Verdict
Not enough evidence
GLP-1 microdosing is an experimental practice without large trial support.
No counted mention yet.
By Arun AgrahriLast reviewed 1 timecoded source
Short answer
Unproven. GLP-1 microdosing has clinical advocates but no large trial, and the advocates use it for different goals: short-term craving control, maintenance, metabolic health or fertility care. Those are separate protocols, not one tested method, so treat any dose as experimental.
GLP-1 drugs are worth taking for people with obesity.
The verdict on GLP-1 Agonists overall. 18 sources: 6 positive, 9 partly, 3 negative
positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.
GLP-1 microdosing is an experimental practice without large trial support.
No counted mention yet.
Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent
GLP-1 microdosing is an experimental practice without large trial support. "Microdosing" a GLP-1 means using a fraction of the standard weight-loss dose. The idea is to keep the metabolic and craving benefits while avoiding nausea, muscle loss and the flatness some people report at full doses.
It is popular right now, the evidence is thin, and its advocates are not describing the same intervention.
Ben Bikman, a metabolic scientist and guest on Rhonda Patrick's show, frames microdosing as a roughly 90-day tool rather than a permanent weight-loss strategy. Combined with behavioral coaching, it helps people rewire cravings for refined carbohydrates before tapering off. Craig Koniver, a guest on Andrew Huberman's show, describes microdosing semaglutide or tirzepatide in his own practice to keep metabolic benefits while limiting side effects like muscle loss.
His version is maintenance, not a course with an end date.
Tyna Moore, a guest on Mark Hyman's show and on The Diary of a CEO, aims at a third group. Her patients are already metabolically optimized and mostly not trying to lose weight, and she doses on the model of low-dose naltrexone. Her reasoning runs through what she calls functional GLP-1 deficiency, and she cites a study showing statins cut the body's own GLP-1 production by half.
Thais Aliabadi and Natalie Crawford, both guests on Huberman's show, use low-dose GLP-1s more narrowly still. For them it is an anti-inflammatory tool in PCOS, endometriosis and fertility care, not a weight drug.
"Should I microdose" is close to the wrong question, because the advocates answer different ones: for how long, for whom, and to do what. Bikman's version has an end date and Koniver's does not. Moore's targets people the drug was never trialed on, and the fertility clinicians are not treating weight at all.
None of them has a trial. All of it is clinical observation from guests. Peter Attia, who devoted an August 2026 episode to peptides, has not addressed GLP-1 microdosing directly.
The closest he comes is a general objection that the wellness peptide field went wide on usage before human efficacy data existed. That is a standard microdosing has not been tested against, not a rebuttal of it.
The mechanism is plausible and the anecdotes are real, but the protocols contradict each other and no large trial has tested any of them. Take it to a prescriber.
Precis membership
The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one. Nothing on this page is held back.
A free account adds
Pro adds
Full GLP-1 Agonists evidence report
The verdict on every claim, and where the sources disagree